Cystic Fibrosis Australia (CFA) welcomes the listing of Alyftrek on the Pharmaceutical Benefits Scheme (PBS), which took effect on 1 February 2026. This listing significantly improves access to this next-generation treatment for eligible Australians living with cystic fibrosis.

Alyftrek is a new prescription medicine for people aged six years and older with cystic fibrosis who have at least one responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It combines three active ingredients – vanzacaftor, tezacaftor and deutivacaftor – which work together to target the underlying genetic cause of the condition.

Changes in the CFTR gene can result in faulty production or function of the CFTR protein, which normally helps regulate salt and water on surfaces in the body such as the lungs. When this process is disrupted, thick, sticky mucus can build up, leading to breathing difficulties and long-term damage to the lungs, digestive system and other organs.

Alyftrek is the first once-daily CFTR modulator and is indicated for a broad range of CFTR gene mutations. By helping control mucus production, it supports improved lung and digestive function and may make treatment routines easier to maintain, encouraging adherence and better long-term health outcomes.

CFA Chief Executive Officer Dr Jo Armstrong said the PBS listing represents an important step forward for the cystic fibrosis community.

“This announcement brings hope to many families across Australia,” Dr Armstrong said. “Access to next-generation therapies like Alyftrek can make a meaningful difference in daily life for people with cystic fibrosis, and the once-daily dosing is an important advancement.”

Dr Armstrong emphasised that the outcome reflects years of advocacy and collaboration.

“This PBS listing is thanks to our remarkable community, our federation members, clinicians, researchers and supporters, and especially people living with cystic fibrosis and their families who shared their stories, insights and lived experience,” she said. “Their voices helped demonstrate why timely access to new treatments is so critical and we are grateful that the Government responded quickly to our request. People should have access to medications they need without delays.”

Cystic Fibrosis Australia will continue working with government, industry and health partners to advocate for further research, and equitable access to therapies for all Australians living with the condition.

“Advancements like this are only possible because of the strength and determination of our community,” Dr Armstrong said. “CFA remains committed to pushing for outcomes like these so that everyone living with cystic fibrosis has access to the treatments they need to live full and productive lives.”

Media enquiries:
Cystic Fibrosis Australia
Dr Jo Armstrong
0405 599 845